RU2005136864A - USE OF OXYCAM COMPOUNDS - Google Patents

USE OF OXYCAM COMPOUNDS Download PDF

Info

Publication number
RU2005136864A
RU2005136864A RU2005136864/15A RU2005136864A RU2005136864A RU 2005136864 A RU2005136864 A RU 2005136864A RU 2005136864/15 A RU2005136864/15 A RU 2005136864/15A RU 2005136864 A RU2005136864 A RU 2005136864A RU 2005136864 A RU2005136864 A RU 2005136864A
Authority
RU
Russia
Prior art keywords
lornoxicam
cox
induction
thiazine
thieno
Prior art date
Application number
RU2005136864/15A
Other languages
Russian (ru)
Other versions
RU2366425C2 (en
Inventor
Дитер БИНДЕР (умер)
Original Assignee
БИНДЕР Ева (AT)
БИНДЕР Ева
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by БИНДЕР Ева (AT), БИНДЕР Ева filed Critical БИНДЕР Ева (AT)
Publication of RU2005136864A publication Critical patent/RU2005136864A/en
Application granted granted Critical
Publication of RU2366425C2 publication Critical patent/RU2366425C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The invention relates to the use of lornoxicam or analogues thereof which inhibit cyclo-oxygenase 1 and cyclo-oxygenase 2 (COX 1 and COX 2), cannot penetrate the blood-brain barrier under physiological conditions, and reduce the prostaglandin E2-induced induction of the amyloid-precursor-protein (APP), for producing a pharmaceutical composition for the treatment or prevention of Alzheimer's disease or arteriosclerosis.

Claims (3)

1. Применение лорноксикама или аналогов лорноксикама, которые ингибируют циклооксигеназу 1 и циклооксигеназу 2 (СОХ 1 и СОХ 2), не могут преодолевать гематоэнцефалический барьер при физиологических условиях, и сокращают индуцированную простогландином Е2 индукцию белка-предшественника амилоидов (АРР), для получения фармацевтической композиции для лечения или предотвращения болезни Альцгеймера (БА) или артериосклероза.1. The use of lornoxicam or analogues of lornoxicam, which inhibit cyclooxygenase 1 and cyclooxygenase 2 (COX 1 and COX 2), cannot overcome the blood-brain barrier under physiological conditions, and reduce the induction of prostoglandin E2 induction of the amyloid precursor protein (APP) to obtain the pharmaceutical composition, to obtain for the treatment or prevention of Alzheimer's disease (AD) or arteriosclerosis. 2. Применение по п.1, отличающееся тем, что введение вещества сопровождается тяжелыми нежелательными побочными действиями на уровне ниже 1%, предпочтительно ниже 0,5%, более предпочтительно ниже 0,1%, в особенности ниже 0,05% пациентов.2. The use according to claim 1, characterized in that the administration of the substance is accompanied by severe undesirable side effects at a level below 1%, preferably below 0.5%, more preferably below 0.1%, in particular below 0.05% of patients. 3. Применение по п.1 или 2, отличающееся тем, что аналог лорноксикама выбран из группы включающей 6-хлор-4-(1-(этоксикарбамоилокси)этокси)-2-метил-N-(2-пиридил)-2Н-тиено-(2,3-е)-1,2-тиазин-3-карбоновой кислоты амид-1,1-диоксид, 6-хлор-4-гидрокси-2-метил-3-(2-пиридил-карбамоил)-2Н-тиено[3,2-е]1,2-тиазин-1,1-диоксид.3. The use according to claim 1 or 2, characterized in that the lornoxicam analog is selected from the group consisting of 6-chloro-4- (1- (ethoxycarbamoyloxy) ethoxy) -2-methyl-N- (2-pyridyl) -2H-thieno - (2,3-e) -1,2-thiazine-3-carboxylic acid amide-1,1-dioxide, 6-chloro-4-hydroxy-2-methyl-3- (2-pyridyl-carbamoyl) -2H thieno [3,2-e] 1,2-thiazine-1,1-dioxide.
RU2005136864/15A 2003-05-27 2004-05-27 Application of oxycam compounds RU2366425C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA819/2003 2003-05-27
AT0081903A AT413944B (en) 2003-05-27 2003-05-27 USE OF OXICAM COMPOUNDS

Publications (2)

Publication Number Publication Date
RU2005136864A true RU2005136864A (en) 2006-06-10
RU2366425C2 RU2366425C2 (en) 2009-09-10

Family

ID=33479909

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005136864/15A RU2366425C2 (en) 2003-05-27 2004-05-27 Application of oxycam compounds

Country Status (13)

Country Link
US (2) US8129370B2 (en)
EP (1) EP1626726B1 (en)
JP (1) JP5597339B2 (en)
KR (1) KR101134244B1 (en)
CN (3) CN101450057A (en)
AT (2) AT413944B (en)
CA (1) CA2526816C (en)
DE (1) DE502004001499D1 (en)
DK (1) DK1626726T3 (en)
ES (1) ES2271893T3 (en)
PL (1) PL1626726T3 (en)
RU (1) RU2366425C2 (en)
WO (1) WO2004105766A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1740585B1 (en) * 2004-04-29 2009-08-19 Binder, Eva HF Enantiomer-pure hexahydropyrrolocyclopentapyridine derivatives
EP2365804B1 (en) * 2008-11-13 2015-05-06 Modgene, Llc Reduction of amyloid-beta load in non-brain tissue
EP2776035B1 (en) 2011-11-01 2016-08-10 Modgene, Llc Compositions and methods for reduction of amyloid-beta load
CN115227655A (en) * 2022-08-17 2022-10-25 海南锦瑞制药有限公司 Preparation method of lornoxicam for injection

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU518216B2 (en) * 1977-09-06 1981-09-17 Hafslund Nycomed Pharma Aktiengesellschaft Thienothiazine derivatives
JPS58146040A (en) * 1982-02-24 1983-08-31 Pioneer Video Kk Optical system information recording original disk
EP0103142B1 (en) 1982-09-09 1987-04-22 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Thieno(2,3-e)-1,2-thiazine derivatives
NZ226477A (en) * 1987-10-29 1990-07-26 Cl Pharma Substituted thieno (2,3-e)-1,2 thiazine derivatives and pharmaceutical compositions
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
AT400437B (en) * 1993-12-14 1995-12-27 Chem Pharm Forsch Gmbh Novel N-heterocyclic thienothiazinecarboxamides, process for their preparation and their use
US5643960A (en) * 1994-04-15 1997-07-01 Duke University Method of delaying onset of alzheimer's disease symptoms
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6043224A (en) * 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
CA2382547A1 (en) * 1999-09-21 2001-03-29 Stephen R. Hanson Methods and compositions for treating platelet-related disosders
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US20020119193A1 (en) * 2000-08-18 2002-08-29 Le Trang T. Oral fast-melt formulation of a cyclooxygenase-2 inhibitor
JP2002363104A (en) 2001-04-04 2002-12-18 Sankyo Co Ltd New medicinal use of inflammatory cytokine production inhibitor
US7008614B2 (en) * 2001-08-20 2006-03-07 Fuji Photo Film Co., Ltd. Liposome containing hydrophobic iodine compound and X-ray contrast medium for radiograph comprising the liposome
US20030225054A1 (en) * 2002-06-03 2003-12-04 Jingwu Duan Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents

Also Published As

Publication number Publication date
WO2004105766A2 (en) 2004-12-09
ATA8192003A (en) 2005-11-15
US8129370B2 (en) 2012-03-06
CA2526816C (en) 2012-11-27
US20090239852A1 (en) 2009-09-24
US20070275958A1 (en) 2007-11-29
JP5597339B2 (en) 2014-10-01
AT413944B (en) 2006-07-15
WO2004105766A3 (en) 2005-03-03
PL1626726T3 (en) 2007-02-28
JP2006528206A (en) 2006-12-14
KR20060017618A (en) 2006-02-24
RU2366425C2 (en) 2009-09-10
DE502004001499D1 (en) 2006-10-26
ES2271893T3 (en) 2007-04-16
CA2526816A1 (en) 2004-12-09
ATE339206T1 (en) 2006-10-15
CN101450057A (en) 2009-06-10
CN102218067A (en) 2011-10-19
EP1626726A2 (en) 2006-02-22
EP1626726B1 (en) 2006-09-13
DK1626726T3 (en) 2006-12-27
KR101134244B1 (en) 2012-04-09
CN1842338A (en) 2006-10-04

Similar Documents

Publication Publication Date Title
TNSN04246A1 (en) BENZOCONDENSIC HETEROARYLAMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND METHODS FOR THEIR USE
EA200200111A1 (en) HIGH-SELECTIVE INHIBITORS OF REVERSE CAPTURE OF NOREPINEFRIN AND METHODS OF THEIR APPLICATION
RU2007120454A (en) Quinuclidine derivatives and their use as antagonists of M3 muscarinic receptors
RU2003114752A (en) TREATMENT OF GASTROINTESTINAL STOMAL TUMORS
EA200301165A1 (en) Drug on the basis of oxycodone
EA200601799A1 (en) HYDRAZIDE-CONTAINING COMPOUNDS - CFTR INHIBITORS AND THEIR APPLICATION
EA200600811A1 (en) NEW TETRAHYDROSPIRO {PIPERIDIN-2,7'-PYRROLO [3,2-b] PYRIDINE} DERIVATIVES AND NEW INDOLA DERIVATIVES, APPLICATION FOR THE TREATMENT OF DISORDERS RELATED TO 5-HT-RECEPTOR
WO2005063745A3 (en) Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
YU37203A (en) Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as ip antagonists
JP2008501801A5 (en)
BR0210293A (en) An aqueous pharmaceutical preparation of cilostazol for parenteral use
IS8096A (en) Use of carbamazepine derivatives to treat patient agitation is dementia sufferers
BR0210392A (en) Compound, methods of treating a patient who has or prevent a patient from contracting a disease or condition and preparing a compound, and, using a compound
JP2017014224A (en) Agent for prevention or treatment of acute-phase pain in herpes zoster-related pain
JPH10511080A (en) Use of halogenated aromatics to treat mammalian cell proliferation
RU2005136864A (en) USE OF OXYCAM COMPOUNDS
EA007952B1 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
RU2006136361A (en) THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMER'S DISEASE
ATE477021T1 (en) 1,3,5-TRIAZEPINE DIONE FOR THE TREATMENT OF MALARIA
JP2006528206A5 (en)
BR0113140A (en) Nonpeptide ccr1 receptor antagonists in combination with cyclosporine a for the treatment of heart transplant rejection
ATE427108T1 (en) MEDICINAL PRODUCTS CONTAINING ANTICHOLINERGICS FOR THE TREATMENT OF DISEASES OF THE URINARY TRACT
HUP0300032A2 (en) Use of compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoreceptor for preparation of pharmaceutical composition
KR101324689B1 (en) Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating apetite disorder
WO2018106184A1 (en) Application of multi-kinase inhibitor

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20110928

PC41 Official registration of the transfer of exclusive right

Effective date: 20131122

MM4A The patent is invalid due to non-payment of fees

Effective date: 20200528